Reply: Low-Dose Tocilizumab With High-Dose Corticosteroids in Patients Hospitalized for COVID-19 Hypoxic Respiratory Failure Improves Mortality Without Increased Infection Risk.
Xian Jie Cindy ChengDiana AltshulerPeter SpieglerShari B BrosnahanPublished in: The Annals of pharmacotherapy (2021)
Keyphrases
- high dose
- low dose
- respiratory failure
- end stage renal disease
- sars cov
- coronavirus disease
- newly diagnosed
- chronic kidney disease
- ejection fraction
- rheumatoid arthritis
- peritoneal dialysis
- stem cell transplantation
- mechanical ventilation
- cardiovascular events
- cardiovascular disease
- coronary artery disease
- juvenile idiopathic arthritis
- systemic lupus erythematosus
- intensive care unit
- patient reported
- respiratory syndrome coronavirus